Sandra and Edward Meyer Cancer Center

You are here

Calendar

All Events

Weill Cornell Medicine, Us TOO New York and Cancer ABCs invite you to join our monthly support group. Please note that this group is open only to men with advanced or metastatic prostate cancer. For more information, contact Joel T. Nowak at CancerABCs@Gmail.com or (516) 445-2026.
6:30pm to 7:00pm
Weill Cornell Medical College B307
Topic: Genomic Subtypes of Prostate Cancer: Moving Towards Clinical Impact Featured Speaker: Christopher E. Barbieri MD, PhD Assistant Professor of Urology, Assistant Professor of Cell and Developmental Biology; Assistant Attending Urologist, Weill Cornell Medicine Directions: Entrance North East corner of East 69th Street and York Ave. Take the “B” elevators next to the stairs to the 3rd floor and follow signs. More information: Following each month's presentation, we hold an informal discussion, providing an opportunity to talk with others who have had similar experiences. Spouses and significant others are encouraged to attend. We meet on the third Thursday of each month and welcome old friends, as well as new. No registration or RSVP is required. Visit: www.ustoonewyork.org E-mail: info@ustoonewyork.org Call: (917) 830-HELP (4357)
6:00pm to 7:00pm
Weill Cornell Medical College B307
Biochemistry and Cell & Developmental Biology Lecturer: Marcus DaSilva Goncalves, M.D., Ph.D. Assistant Professor, Dept. of Medicine Weill Cornell Medicine
12:00pm to 1:00pm
WCM A106
The Meyer Cancer Center Seminar Series presents: Maria "Ken" Figueroa, M.D. Associate Professor of Human Genetics Co-Leader, Cancer Epigenetics Program Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine
4:00pm to 7:00pm
Belfer Research Building Belfer Research Building, 204 A/B/C
New York City’s most prestigious prostate cancer treatment centers are joining forces to offer this free educational event for all those affected by the disease. Led by experts from Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Medical Center and Memorial Sloan Kettering Cancer Center, this premier summit aims to connect patients, loved ones, caregivers and healthcare practitioners to explore critical prostate cancer topics. Please register to reserve your space at this free community event.
8:00am to 1:00pm
New York Academy of Medicine
Biochemistry and Cell & Developmental Biology Lecturer: Andrew Stewart, M.D. Director, Diabetes Obesity and Metabolism Institute Professor, Dept. of Medicine Icahn School of Medicine at Mount Sinai
12:00pm to 1:00pm
WCM A106
Join us on October 17-20, 2018 for the 18th annual Lymphoma & Myeloma Congress. This program features four days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders. Target Audience This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. Learning Objectives Upon successful completion of these educational activities, participants should be better able to: Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignanciesDefine mechanisms of action of current and emerging agents for hematologic malignanciesAssess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignanciesFormulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignanciesEvaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignanciesCongress Chair Morton Coleman, MD Co-Chair, Lymphoma Session John P. Leonard, MD Co-Chair, Myeloma Session Ruben Niesvizky, MD Co-Chair, CLL Session Richard R. Furman, MD Co-Chair, Acute Leukemia and Hematologic Malignancies Session Gail J. Roboz, MD Please visit lymphomamyeloma.com for full agenda and accreditation details
7:00am to 7:00pm
Sheraton New York Times Square Hotel
Join us on October 17-20, 2018 for the 18th annual Lymphoma & Myeloma Congress. This program features four days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders. Target Audience This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. Learning Objectives Upon successful completion of these educational activities, participants should be better able to: Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignanciesDefine mechanisms of action of current and emerging agents for hematologic malignanciesAssess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignanciesFormulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignanciesEvaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignanciesCongress Chair Morton Coleman, MD Co-Chair, Lymphoma Session John P. Leonard, MD Co-Chair, Myeloma Session Ruben Niesvizky, MD Co-Chair, CLL Session Richard R. Furman, MD Co-Chair, Acute Leukemia and Hematologic Malignancies Session Gail J. Roboz, MD Please visit lymphomamyeloma.com for full agenda and accreditation details
7:00am to 7:00pm
Sheraton New York Times Square Hotel
Biochemistry and Cell & Developmental Biology Lecturer: Michael Hoppa, Ph.D. Assistant Professor Dartmouth College
12:00pm to 1:00pm
WCM A106
Join us on October 17-20, 2018 for the 18th annual Lymphoma & Myeloma Congress. This program features four days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders. Target Audience This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. Learning Objectives Upon successful completion of these educational activities, participants should be better able to: Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignanciesDefine mechanisms of action of current and emerging agents for hematologic malignanciesAssess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignanciesFormulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignanciesEvaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignanciesCongress Chair Morton Coleman, MD Co-Chair, Lymphoma Session John P. Leonard, MD Co-Chair, Myeloma Session Ruben Niesvizky, MD Co-Chair, CLL Session Richard R. Furman, MD Co-Chair, Acute Leukemia and Hematologic Malignancies Session Gail J. Roboz, MD Please visit lymphomamyeloma.com for full agenda and accreditation details
7:00am to 7:00pm
Sheraton New York Times Square Hotel
Join us on October 17-20, 2018 for the 18th annual Lymphoma & Myeloma Congress. This program features four days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders. Target Audience This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. Learning Objectives Upon successful completion of these educational activities, participants should be better able to: Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignanciesDefine mechanisms of action of current and emerging agents for hematologic malignanciesAssess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignanciesFormulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignanciesEvaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignanciesCongress Chair Morton Coleman, MD Co-Chair, Lymphoma Session John P. Leonard, MD Co-Chair, Myeloma Session Ruben Niesvizky, MD Co-Chair, CLL Session Richard R. Furman, MD Co-Chair, Acute Leukemia and Hematologic Malignancies Session Gail J. Roboz, MD Please visit lymphomamyeloma.com for full agenda and accreditation details
7:00am to 7:00pm
Sheraton New York Times Square Hotel